Brief: AIM Vaccine Says FY Revenue RMB1.19 Billion
28/03/2024 01:38
March 28 (Reuters) - AIM Vaccine Co Ltd 6660.HK :
* FY REVENUE RMB1.19 BILLION VERSUS RMB1.26 BILLION
* FY LOSS ATTRIBUTABLE RMB1.30 BILLION VERSUS LOSS RMB319.6
MILLION
* EXPECT TO MAKE SIGNIFICANT PROGRESS IN VACCINE RESEARCH
AND
DEVELOPMENT IN 2024
Further company coverage: 6660.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine